The effect on hypertension of hydrochlorothiazide 100 mg daily plus timolol 20-60 mg daily versus hydrochlorothiazide plus placebo and of hydrochlorothiazide plus timolol plus hydralazine 40-200 mg daily versus hydrochlorothiazide plus placebo plus hydralazine was evaluated in a double-blind, randomized, crossover study in 38 patients with hypertension.
TIMOLOL IS A NEW beta-adrenergic blocking drug with no membrane stabilizing effect and no intrinsic sympathomimetic activity which has been found effective as an antihypertensive agent. l-6 Timolol causes a marked depression of plasma renin activity.4 6 However, the hypotensive action of timolol cannot be correlated with its effect on plasma renin activity.4 ' Franciosa and Freis found that after five weeks of treatment, timolol did not affect cardiac output.' However, we found that after five weeks of treatment, equipotent doses of timolol and of propranolol caused similar hemodynamic effects including similar depression of cardiac index.' Per Lund Johansen demonstrated that after one year of treatment with timolol, the mean resting supine cardiac index decreased 28%, the mean resting sitting cardiac index decreased 32%, and the mean cardiac index during exercise decreased 25-32%.' Thus, blood pressure lowering may be related primarily to the cardiac effect of timolol.
The combination of a diuretic plus a beta-adrenergic blocking drug6-8 or of a diuretic plus a beta-adrenergic blocking drug plus a vasodilator7' 1 " may be very effective in the treatment of essential hypertension. Therefore, we performed a double-blind, randomized, crossover study evaluating the hypotensive effect of timolol plus hydrochlorothiazide versus hydrochlorothiazide, of placebo plus hydrochlorothiazide versus hydrochlorothiazide, of timolol plus hydrochlorothiazide plus hydralazine versus timolol plus hydrochlorothiazide, and of placebo plus hydrochlorothiazide plus hydralazine versus placebo plus hydrochlorothiazide in patients with essential hypertension and a supine diastolic blood pressure between 104-130 mm Hg after four weeks of hydrochlorothiazide 100 mg daily (table 1). The results of this study are reported here.
Materials and Methods
After two weeks of no medication, 52 patients with essential hypertension who then had a supine diastolic blood pressure between 110 and 132 mm Hg received hydrochlorothiazide 100 mg daily for four weeks. Thirteen patients whose supine diastolic blood pressure fell below 100 chlorothiazide plus placebo in lowering both supine and standing systolic and diastolic blood pressures. Hydrochlorothiazide plus timolol plus hydralazine was a very effective regimen in lowering both supine and standing systolic and diastolic blood pressures. The patients tolerated this regimen well with greater hypotensive activity and a lower incidence of side effects than on hydrochlorothiazide plus placebo plus hydralazine. mm Hg after four weeks of hydrochlorothiazide were excluded from the study. One patient randomized initially to hydrochlorothiazide plus placebo dropped out of the study after two days of hydrochlorothiazide plus placebo because she moved.
Thirty-eight men, 33-65 years (mean age 52.4 ± 6.7 years), with a supine diastolic blood pressure > 104 mm Hg after four weeks of hydrochlorothiazide 100 mg daily completed this double-blind, randomized, crossover study. Twenty-three of the 38 subjects were Caucasian, 13 subjects were black, and two subjects were from other racial backgrounds. On a normal salt diet and after two weeks of no medication, five of 38 subjects (13%) had high plasma renin activity, 23 of 38 patients (6 1%) had normal plasma renin activity, and 10 of 38 subjects (26%) had low plasma renin activity.
The blood urea nitrogen, serum creatinine, serum potassium, and liver function tests were normal in all patients. None of the patients had coronary heart disease, valvular heart disease, a history of cerebrovascular disease, a history of congestive heart failure, sinus bradycardia, bundle branch block, atrioventricular block, chronic obstructive lung disease, a history of bronchial asthma, allergic rhinitis, peripheral vascular disease, or diabetes mellitus requiring hypoglycemic medication. The patients were maintained on a normal salt diet during the study. Except for potassium chloride, none of the 38 study patients took any medication other than the study medications during this study. Informed consent was obtained from all participants.
Supine and upright blood pressures measured with a mercury sphygmomanometer and supine heart rates were recorded on an outpatient basis in all patients, and the results of two blood pressures and heart rates during each visit were averaged in the control period and every two weeks in the 32 weeks on drug treatment. The supine measurements were taken after five minutes of rest in that position, and the upright measurements were taken two minutes after standing.
All 38 patients received hydrochlorothiazide 100 mg daily initially for four weeks. During the first treatment period (table 1), 21 patients were randomized in a double-blind crossover study to hydrochlorothiazide 100 mg daily plus timolol 20 mg to 60 mg daily for six weeks, and 17 patients were randomized to hydrochlorothiazide 100 mg daily plus placebo for six weeks. The optimal dose of timolol 20-60 mg daily was titrated for each patient. If the supine diastolic blood pressure at the end of the first treatment period was below 90 mm Hg, the patient received for six weeks during the second treatment period hydrochlorothiazide 100 mg daily plus the optimal dose of timolol or placebo. If the supine diastolic blood pressure at the end of the first treatment period was 90 mm Hg or higher, the patient received for six weeks hydrochlorothiazide 100 mg daily plus the optimal dose of timolol or placebo plus hydralazine 40-200 mg daily. The optimal dose of hydralazine 40-200 mg daily was titrated for each patient.
After completion of the second treatment period, all 38 patients received hydrochlorothiazide 100 mg daily for four weeks. During the third treatment period, the patients randomized to hydrochlorothiazide plus timolol during the first treatment period received for six weeks hydrochlorothiazide 100 mg daily plus placebo; the patients randomized to hydrochlorothiazide plus placebo during the first treatment period received hydrochlorothiazide 100 mg daily plus timolol 20-60 mg daily during the third treatment period.
If the supine diastolic blood pressure at the end of the third treatment period was below 90 mm Hg, the patient received for six weeks during the fourth treatment period hydrochlorothiazide 100 mg daily plus the optimal dose of timolol or placebo during the third treatment period. If the supine diastolic blood pressure at the end of the third treatment period was 90 mm Hg or higher, the patient received for six weeks hydrochlorothiazide 100 mg daily plus the optimal dose of timolol or placebo plus hydralazine 40-200 mg daily. Plasma renin activity was measured by radioimmunoassay" by Bioscience Laboratories with the patients on a normal salt diet, in the control period, at the end of each hydrochlorothiazide baseline period, and at the end of each of the four treatment periods.
Within group comparisons were performed using Wilcoxon's signed rank test. Between group comparisons were performed using the Kruskal-Wallis rank procedure. Nominal data were analyzed using a chi-square test or Fisher's exact test or Mc Nemar's test, as appropriate.
In the control period, at the end of each hydrochlorothiazide baseline period, and at the end of each of the four treatment periods, electrocardiograms and chest roentgenograms were obtained, and samples of blood and urine were obtained for the following determinations: hemoglobin, hematocrit, white blood count, differential white count, platelet count, blood urea nitrogen, serum creatinine, fasting blood sugar, serum cholesterol, serum alkaline phosphatase, serum glutamic oxaloacetic transaminase, total serum bilirubin, serum uric acid, serum sodium, potassium, and chloride, LE cell preparation, and serum antinuclear antibody titer.
Results
No adverse symptoms occurred in any patient on hydrochlorothiazide alone or on hydrochlorothiazide plus placebo. Fatigue occurred in one of 38 patients (3%) on hydrochlorothiazide plus timolol. Mild headaches occurred in two of 20 patients (10%) on hydrochlorothiazide plus timolol plus hydralazine. Mild or moderately severe headaches, palpitations, or dizziness occurred in 10 of 34 patients (29%) on hydrochlorothiazide plus placebo plus hydralazine. No laboratory evidence of toxicity occurred in any patient during the study. Table 2 indicates the mean systolic and diastolic blood pressures and heart rates ± 1 SD during the baseline periods and end of first treatment periods for 21 patients randomized to timolol plus hydrochlorothiazide and 17 patients randomized to placebo plus hydrochlorothiazide. Table 2 also shows the mean plasma renin activity for 21 patients randomized to timolol plus hydrochlorothiazide and 15 patients randomized to placebo plus hydrochlorothiazide. Table 3 reveals the mean systolic and diastolic blood pressures and heart rates ± 1 SD during the baseline periods and end of third treatment periods for 17 patients ran- (ng/ml/hr) i 5.39 i 1.19
1.77 -2.78 SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; PRA = plasma renin activity; HCTZ = hydrochlorothiazide 100 mg daily; T = Timolol, mean dose 47 mg daily; P = placebo; *P <0.01 for HCTZ + T minus respective HCTZ compared to HCTZ + P minus respective HCTZ; t = 20 for PRA. domized to timolol plus hydrochlorothiazide and 21 patients randomized to placebo plus hydrochlorothiazide. Table 3 also indicates the mean plasma renin activity for 17 patients randomized to timolol plus hydrochlorothiazide and 20 patients randomized to placebo plus hydrochlorothiazide. A reduction in supine diastolic blood pressure > 10 mm Hg occurred in 33 of 38 patients (87%) on timolol plus hydrochlorothiazide and in 7 of 38 patients (18%) on hydrochlorothiazide plus placebo (P < 0.01).
Pearson's product-moment correlation coefficient, r, was computed by relating changes from baseline hydrochlorothiazide therapy in plasma renin activity with those in supine and standing systolic and diastolic blood pressures at the end of six weeks of treatment with timolol plus hydrochlorothiazide during treatmenr periods I and 3 (table 4). A poor correlation was observed between the antihypertensive effect of timolol and the lowering of plasma renin activity. Table 5 shows the mean systolic and diastolic blood pressures and heart rates ± 1 SD during the baseline periods and end of second treatment periods for 14 patients randomized to timolol plus hydrochlorothiazide and 15 patients randomized to placebo plus hydrochlorothiazide plus hydralazine. Table 6 reveals the mean systolic and diastolic blood pressures and heart rates ± 1 SD during the end of the first treatment periods and second treatment periods for 14 patients randomized to timolol plus hydrochlorothiazide plus hydralazine and 15 patients randomized to placebo plus hydrochlorothiazide plus hydralazine. Table 7 indicates the mean systolic and diastolic blood pressures and heart rates ± I SD during the baseline periods and end of fourth treatment periods for six patients randomized to timolol plus hydrochlorothiazide plus hydralazine and 19 patients randomized to placebo plus hydrochlorothiazide plus hydralazine. Table 8 shows the mean systolic and diastolic blood pressures and heart rates ± 1 SD during the end of the third and fourth treatment periods for six patients randomized to timolol plus hydrochlorothiazide plus hydralazine and 19 patients randomized to placebo plus hydrochlorothiazide plus hydralazine.
Seventeen patients received hydralazine during both treatment periods 2 and 4. Table 9 indicates the mean systolic and diastolic blood pressures and heart rates ± 1 SD in these 103.0t (mm Hg) -5.4 5.3 i 7.5 9.9 SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HCTZ = hydrochlorothiazide 100 mg daily; T = timolol 60 mg daily; P = placebo; HZ = hydralazine, mean dose 103 mg daily on HCTZ + T, and 192 mg daily on HCTZ + P; * P <0.01 for HCTZ + T + HZ minus respective HCTZ or for HCTZ + P + HZ minus respective HCTZ; tP <0.05 for HCTZ + T + HZ minus respective HCTZ or for HCTZ + P + HZ minus respective HCTZ; $P <0.01 for HCTZ + T + HZ minus respective HCTZ compared to HCTZ + P + HZ minus respective HCTZ; §a greater dose of HZ wvas taken with HCTZ + P than with HCTZ + T, P <0.01.
17 patients during the baseline periods, after treatment with hydrochlorothiazide plus timolol plus hydralazine, and after treatment with hydrochlorothiazide plus placebo plus hydralazine.
The mean values for supine and standing systolic and diastolic blood pressures and heart rates for the patients not receiving hydralazine on hydrochlorothiazide plus timolol or on hydrochlorothiazide plus placebo were similar at the end of treatment periods 2 to the values at the end of treatment periods 1 and were similar at the end of treatment periods 4 to the values at the end of treatment periods 3.
Discussion
Chalmers and associates showed that hydrochlorothiazide 50 mg daily and timolol 30 mg daily are effective (mm Hg) i 7.1 9.9 7.4 d=11.4 SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HCTZ = hydrochlorothiazide 100 mg daily; T = timolol, mean dose 52 mg daily; P = placebo; HZ = hydralazine, mean dose 114 mg daily on HCTZ + T, and 181 mg daily on HCTZ + P; *P <0.01 for HCTZ + T + HZ minus respective HCTZ compared to HCTZ + P + HZ minus respective HCTZ.
antihypertensive agents, and that when used in combination, their effects were additive. 6 The antihypertensive effect of timolol was found to be independent of changes in plasma renin activity.
Our data clearly indicate that timolol plus hydrochlorothiazide was more effective than placebo plus hydrochlorothiazide in lowering supine and standing systolic and diastolic blood pressures. Although timolol caused a reduction in plasma renin activity, a poor correlation was found between the antihypertensive action of timolol and the lowering of plasma renin activity.
Our data also show that hydralazine was effective in lowering supine and standing systolic and diastolic blood pressures in patients on timolol plus hydrochlorothiazide and in patients on placebo plus hydrochlorothiazide. However, the hypotensive effect of timolol plus hydrochlorothiazide plus hydralazine was greater than the hypotensive effect of placebo plus hydrochlorothiazide plus hydralazine. Moreover, the patients needed a lower dose of hydralazine if they were on timolol plus hydrochlorothiazide and had fewer side effects due to hydralazine if they were on timolol plus hydrochlorothiazide.
In conclusion, the combination of the diuretic hydrochlorothiazide plus the beta-blocker timolol plus the vasodilator hydralazine was found to be a very effective regimen in lowering both supine and standing systolic and diastolic blood pressures. This treatment regimen was not associated with any laboratory toxicity. Moreover, the patients tolerated this regimen well with greater hypotensive activity and a lower incidence of side effects on this treatment regimen than on hydrochlorothiazide plus placebo plus hydralazine.
